Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Condition:   Neuroblastoma Interventions:   Drug: Naxitamab monotherapy;   Drug: GM-CSF;   Drug: Irinotecan;   Drug: Temozolomide;   Drug: Naxitamab in combination therapy;   Drug: GM-CSF with combination regimen;   Drug: Sintilimab Sponsors:   Sun Yat-sen University;   Hainan General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials